ATE498409T1 - Peg-uricase konjugate und verwendung davon - Google Patents

Peg-uricase konjugate und verwendung davon

Info

Publication number: ATE498409T1
Authority: AT; Austria
Prior art keywords: peg; uricase; kda; poly; uricase conjugates
Prior art date: 1998-08-06

Application number

AT05011069T

Other languages

English (en)

Inventor

David Williams L

Michael S Hershfield

Susan J Kelly

Mark G P Saifer

Merry R Sherman

Original Assignee

Mountain View Pharmaceuticals

Univ Duke

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-06

Filing date

1999-08-02

Publication date

2011-03-15

1999-08-02 Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE498409T1 publication Critical patent/ATE498409T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT05011069T 1998-08-06 1999-08-02 Peg-uricase konjugate und verwendung davon ATE498409T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US21931898P	1998-08-06	1998-08-06

Publications (1)

Publication Number	Publication Date
ATE498409T1 true ATE498409T1 (de)	2011-03-15

Family

ID=22818799

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT05011069T ATE498409T1 (de)	1998-08-06	1999-08-02	Peg-uricase konjugate und verwendung davon
AT99937745T ATE298251T1 (de)	1998-08-06	1999-08-02	Peg-uricase konjugate und verwendung davon

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT99937745T ATE298251T1 (de)	1998-08-06	1999-08-02	Peg-uricase konjugate und verwendung davon

Country Status (11)

Country	Link
US (11)	US6576235B1 (de)
EP (3)	EP1588716B1 (de)
CN (3)	CN1896231B (de)
AT (2)	ATE498409T1 (de)
CA (2)	CA2728907C (de)
CY (2)	CY1112287T1 (de)
DE (2)	DE69943205D1 (de)
DK (4)	DK1100542T3 (de)
ES (4)	ES2404074T3 (de)
PT (4)	PT1588716E (de)
ZA (1)	ZA200101814B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060188971A1 (en) *	1998-08-06	2006-08-24	Duke University	Urate oxidase
WO2000008196A2 (en)	1998-08-06	2000-02-17	Duke University	Urate oxidase
US6783965B1 (en) *	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE498409T1 (de) *	1998-08-06	2011-03-15	Mountain View Pharmaceuticals	Peg-uricase konjugate und verwendung davon
US6913915B2 (en) *	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
ES2348230T3 (es) *	2002-06-07	2010-12-01	Dyax Corp.	Prevención y reducción de la isquemia.
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US8129330B2 (en) *	2002-09-30	2012-03-06	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en)	2002-09-30	2004-04-01	Mountain View Pharmaceuticals, Inc.	Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GEP20084487B (en) *	2002-12-26	2008-09-25	Mountain View Pharmaceuticals	Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
JP5207590B2 (ja) *	2002-12-26	2013-06-12	マウンテンビューファーマシューティカルズ，インコーポレイテッド	増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US7919118B2 (en) *	2003-05-12	2011-04-05	Affymax, Inc.	Spacer moiety for poly (ethylene glycol) modified peptide based compounds
CN1820024B (zh) *	2003-05-12	2011-06-22	阿费麦克斯公司	新的聚(乙二醇)修饰的化合物及其用途
AU2004238868B2 (en) *	2003-05-12	2010-01-21	Affymax, Inc.	Peptides that bind to the erythropoietin receptor
US20050089515A1 (en) *	2003-08-29	2005-04-28	Dyax Corp.	Poly-pegylated protease inhibitors
RU2298560C2 (ru) *	2004-04-30	2007-05-10	Открытое Акционерное Общество "Верофарм"	Конъюгаты белка и производного полиэтиленгликоля, фармацевтическая композиция, способ борьбы с вирусной инфекцией
JP2008507591A (ja) *	2004-05-21	2008-03-13	ゼンコー・インコーポレイテッド	免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20080317728A1 (en) *	2004-06-21	2008-12-25	University Of Florida Research Foundation, Inc.	Lowering Uric Acid to Prevent or Accelerate Recovery of Acute Renal Failure
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) *	2004-11-11	2008-06-12	アフィーマックス・インコーポレイテッド	エリスロポエチンレセプターに結合する新規ペプチド
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) *	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
MX2007012548A (es)	2005-04-11	2008-03-11	Savient Pharmaceuticals Inc	Formas variantes de urato oxidasa y uso de las mismas.
SG161247A1 (en)	2005-04-11	2010-05-27	Savient Pharmaceuticals Inc	Variant forms of urate oxidase and use thereof
EP1883425A1 (de) *	2005-05-23	2008-02-06	Universite De Geneve	Injizierbare superparamagnetische nanoteilchen zur behandlung von hyperthermie und verwendung zur bildung eines hyperthermischen implantats
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
JP5033177B2 (ja) *	2006-04-12	2012-09-26	サビエントファーマセウティカルズインク．	陽イオン界面活性剤によるタンパク質の精製
CN101302501B (zh) *	2007-05-10	2012-07-04	刘国安	聚乙二醇化尿酸氧化酶化合物及其制备方法和其制剂及应用
US20090075887A1 (en) *	2007-08-21	2009-03-19	Genzyme Corporation	Treatment with Kallikrein Inhibitors
EP2207890A4 (de) *	2007-10-05	2010-12-15	Barofold Inc	Hochdruckbehandlung aggregierter interferone
EP2271750A4 (de) *	2008-03-24	2011-07-27	Althea Technologies Inc	Uricase-zusammensetzungen und verwendungsverfahren
EP2165705A1 (de)	2008-09-18	2010-03-24	Centre National de la Recherche Scientifique (CNRS)	Verwendung einer Verbindung mit der Fähigkeit zur Senkung des Harnsäureniveaus zur Prävention und/oder Behandlung von Lungenentzündung und -fibrose
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN101875922B (zh) *	2009-04-30	2012-02-22	重庆医科大学	一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
US9377454B2 (en)	2009-06-25	2016-06-28	Crealta Pharmaceuticals Llc	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102051348B (zh) *	2009-10-27	2012-10-03	重庆富进生物医药有限公司	人源化重组尿酸酶及其突变体
SMT201800552T1 (it)	2010-01-06	2018-11-09	Dyax Corp	Proteine che legano la callicreina plasmatica
CN101928704A (zh) *	2010-03-04	2010-12-29	杭州北斗生物技术有限公司	黄曲霉尿酸氧化酶的聚乙二醇修饰物及其制备方法
US8940861B2 (en) *	2010-04-08	2015-01-27	Georgia Tech Research Corporation	Variants of ancestral uricases and uses thereof
KR102320178B1 (ko)	2011-01-06	2021-11-02	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질
CN102634492B (zh) *	2011-02-14	2015-06-10	重庆富进生物医药有限公司	聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) *	2011-04-28	2015-03-18	杭州俊丰生物工程有限公司	人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
CN102260653B (zh) *	2011-06-30	2013-04-03	荣俊	一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
US10481164B2 (en) *	2012-03-26	2019-11-19	Amgen Inc.	Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
CN105593215B (zh)	2013-07-11	2019-01-15	安吉奥斯医药品有限公司	用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015010297A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
NZ723859A (en)	2014-03-14	2023-01-27	Servier Lab	Pharmaceutical compositions of therapeutically active compounds and their uses
US10428158B2 (en)	2014-03-27	2019-10-01	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
US10198063B1 (en) *	2014-11-06	2019-02-05	Avago Technologies International Sales Pte. Limited	Average power saving modes and power architecture for read channel product
US11098289B2 (en) *	2015-05-15	2021-08-24	Medimmune, Llc	Uricase sequences and methods of treatment
FI3362065T3 (fi)	2015-10-15	2024-06-19	Servier Lab	Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
KR102699521B1 (ko)	2015-10-15	2024-08-26	르 라보레또레 쎄르비에르	악성 종양의 치료를 위한 조합물 요법
EP3387018A1 (de)	2015-12-11	2018-10-17	Dyax Corp.	Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
CN105412942B (zh) *	2015-12-23	2019-02-26	沈阳三生制药有限责任公司	聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN116637177A (zh)	2016-11-11	2023-08-25	好利恩治疗美国公司	泼尼松和尿酸酶分子的组合疗法及其用途
CN108103079B (zh) *	2017-06-20	2021-07-13	北京锦篮基因科技有限公司	一种高尿酸血症的基因治疗药物
AU2018297309A1 (en)	2017-07-07	2020-01-30	Allena Pharmaceuticals, Inc.	Recombinant uricase enzyme
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
US10953107B2 (en) *	2018-06-15	2021-03-23	Trustees Of Boston University	Polypeptide compositions and methods for site-specific targeting of therapeutic agents
WO2020160322A1 (en)	2019-01-30	2020-08-06	Horizon Pharma Rheumatology Llc	Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020160325A1 (en)	2019-01-30	2020-08-06	Horizon Pharma Rheumatology Llc	Reducing immunogenicity to pegloticase
KR20250041198A (ko)	2019-05-10	2025-03-25	피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭)	폴리에틸렌 글리콜로 변형된 요산 산화효소
EP4090427A1 (de)	2020-01-13	2022-11-23	Takeda Pharmaceutical Company Limited	Plasma-kallikrein-inhibitoren und verwendungen davon zur pädiatrischen behandlung von hereditärem angioödem
CN113144174B (zh) *	2020-01-22	2023-07-04	杭州远大生物制药有限公司	治疗高尿酸相关性疾病的药物
EP4588513A3 (de)	2020-08-10	2025-10-22	Horizon Therapeutics USA, Inc.	Verfahren zur behandlung von gicht
MX2023005235A (es) *	2020-11-03	2023-10-16	Protalix Ltd	Uricasa modificada y usos de la misma.
KR20220077590A (ko)	2020-12-02	2022-06-09	주식회사 프로앱텍	Candida Utilis 유래 요산산화효소-알부민 복합체 및 이의 제조 방법
CN115197922B (zh) *	2021-04-09	2024-05-14	派格生物医药(苏州)股份有限公司	尿酸酶或其同功异型物及其制备方法
CN114262405B (zh) *	2021-12-24	2023-02-07	浙江震东新材料有限公司	一种短链含氟防水防油剂共聚物及其制备方法
CN114813998B (zh) *	2022-03-24	2023-05-23	天津键凯科技有限公司	一种聚合物的检测方法
CN116086924B (zh) *	2022-12-30	2026-03-31	江苏尤里卡生物科技有限公司	一种制备尿激酶的尿液分离回收系统
CN121752726A (zh)	2023-07-11	2026-03-27	克里雅疗法股份有限公司	用于递送编码尿酸酶的核酸的载体构建体及其使用方法
US12269875B2 (en)	2023-08-03	2025-04-08	Jeff R. Peterson	Gout flare prevention methods using IL-1BETA blockers
CN120137926B (zh) *	2025-05-14	2025-09-05	杭州师范大学	一种嗜热毁丝霉尿酸酶突变体及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279486C (de)
US3451996A (en)	1968-02-12	1969-06-24	Thompson Farms Co	Method for the preparation of heparin
US3616231A (en)	1968-11-14	1971-10-26	Boehringer Mannheim Gmbh	Process for the production of uricase
US3931399A (en)	1970-12-22	1976-01-06	Behringwerke Aktiengesellschaft	Process for isolating a fibrin-stabilizing factor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4169764A (en)	1975-08-13	1979-10-02	Ajinomoto Co., Inc.	Process for production of urokinase
US4141973A (en)	1975-10-17	1979-02-27	Biotrics, Inc.	Ultrapure hyaluronic acid and the use thereof
US4064010A (en)	1976-07-21	1977-12-20	Eastman Kodak Company	Purification of uricase
US4301153A (en)	1977-03-21	1981-11-17	Riker Laboratories, Inc.	Heparin preparation
US4312979A (en)	1978-04-20	1982-01-26	Toyo Soda Manufacturing Co., Ltd.	Polysaccharides containing allose
US4425431A (en)	1978-04-20	1984-01-10	Toyo Soda Manufacturing Co., Ltd.	Production of an allose-containing polysaccharide
JPS6031472B2 (ja)	1978-12-14	1985-07-22	協和醗酵工業株式会社	酸性ウリカ−ゼ
US4251431A (en)	1979-01-16	1981-02-17	Shell Oil Company	Lubricating greases
JPS5599189A (en)	1979-01-22	1980-07-28	Mihama Hisaharu	Modified uricase free from antigenicity and its preparation
JPS55135590A (en)	1979-04-05	1980-10-22	Mihama Hisaharu	Modified asparaginase and uricase and their preparation
DE2916711A1 (de)	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
FR2475900A1 (fr)	1980-02-20	1981-08-21	Fabre Sa Pierre	Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH651308A5 (de)	1980-07-01	1985-09-13	Hoffmann La Roche	Interferone und deren herstellung.
JPS5740503A (en)	1980-08-22	1982-03-06	Seikagaku Kogyo Co Ltd	Separation of saccharides
FR2497006A1 (fr)	1980-12-24	1982-06-25	Ind Electro Ste Gle	Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en)	1981-05-20	1982-11-26	Toyobo Co Ltd	Modified polypeptide
DE3126759A1 (de)	1981-07-07	1983-01-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4485176A (en)	1982-06-28	1984-11-27	E. I. Du Pont De Nemours & Company	Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (de)	1982-11-23	1986-12-03	The Wellcome Foundation Limited	Komplexe, Verfahren zu deren Herstellung und diese Komplexe enthaltende Zusammensetzungen
US4732863A (en)	1984-12-31	1988-03-22	University Of New Mexico	PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja)	1985-06-05	1994-09-14	サッポロビール株式会社	ウリカ−ゼおよびその製造法
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (ja)	1985-06-26	1996-08-14	シタスコーポレイション	ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en)	1985-12-11	1990-06-14	Natinco Nv	Solubilization of protein aggregates
DD279486A1 (de)	1986-03-10	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja)	1986-04-23	1987-03-10	Mihama Hisaharu	修飾ウリカ−ゼ
AU612133B2 (en)	1987-02-20	1991-07-04	Natinco Nv	Production of proteins in active forms
CA1305285C (en)	1987-04-21	1992-07-14	Malcolm Roy Brandon	Production of proteins in active forms
AU609824B2 (en)	1987-06-15	1991-05-09	Southern Cross Biotech Pty Ltd.	Production of proteins in active forms
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en)	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja)	1988-02-24	1989-08-30	Hoechst Japan Kk	末熟児頭蓋内出血阻止剤
US4945086A (en)	1988-05-03	1990-07-31	The Board Of Trustees Of The Leland Stanford Junior University	Smooth muscle cell growth inhibitor
US5955336A (en)	1988-08-17	1999-09-21	Toyo Boseki Kabushiki Kaisha	DNA sequence for uricase and manufacturing process of uricase
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en)	1988-10-20	1988-11-23	Royal Free Hosp School Med	Fractionation process
JP3148208B2 (ja)	1988-10-31	2001-03-19	富士ゼロックス株式会社	マルチ出力トレイ付プリントサーバおよびプリントシステム
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en)	1989-07-07	1991-04-23	Macfarlane Donald E	Process for purifying DNA and RNA using cationic detergents
KR0159107B1 (ko)	1989-07-13	1998-11-16	쟝 르쌍드뢰	우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
NZ234453A (en)	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5286637A (en)	1989-08-07	1994-02-15	Debiopharm, S.A.	Biologically active drug polymer derivatives and method for preparing same
US5362641A (en)	1989-08-23	1994-11-08	Hadassah Medical Organization Kiryat Hadassah	Heparanase derived from human Sk-Hep-1 cell line
JPH03148298A (ja)	1989-11-01	1991-06-25	Sumitomo Pharmaceut Co Ltd	修飾ペプチドおよびその製造方法
US5766897A (en)	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
US5653974A (en)	1990-10-18	1997-08-05	Board Of Regents,The University Of Texas System	Preparation and characterization of liposomal formulations of tumor necrosis factor
ATE240740T1 (de)	1991-03-15	2003-06-15	Amgen Inc	Pegylation von polypeptiden
DE69230613T2 (de)	1991-07-02	2000-12-28	Inhale Inc	Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
YU66892A (sh)	1991-08-20	1995-10-24	Hoechst Ag.	Fosfoinositolglikan - peptid sa delovanjem kao insulin
US5298643A (en)	1992-12-22	1994-03-29	Enzon, Inc.	Aryl imidate activated polyalkylene oxides
US5321095A (en)	1993-02-02	1994-06-14	Enzon, Inc.	Azlactone activated polyalkylene oxides
AU6240494A (en)	1993-02-16	1994-09-14	Enzon, Inc.	Ribosome inactivating protein compositions having reduced antigenicity
US6385312B1 (en)	1993-02-22	2002-05-07	Murex Securities, Ltd.	Automatic routing and information system for telephonic services
JP3875730B2 (ja)	1993-02-22	2007-01-31	サノフィ・アベンティス株式会社	自己免疫疾患の予防治療剤
US5298410A (en)	1993-02-25	1994-03-29	Sterling Winthrop Inc.	Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
DE69426598T2 (de)	1993-04-09	2001-08-09	Bio-Technology General Corp., Iselin	Neues Peptid mit einer inhibierenden Aktivität gegen Faktor Xa
US5783421A (en)	1993-04-09	1998-07-21	Bio-Technology General Corp.	DNA encoding novel polypeptide having Factor Xa inhibitory activity
WO1994023740A1 (en)	1993-04-22	1994-10-27	Celtrix Pharmaceuticals, Inc.	Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en)	1993-06-21	1995-01-17	Enzon, Inc.	Site specific synthesis of conjugated peptides
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
JPH09504174A (ja)	1993-10-29	1997-04-28	インサイトファーマシューティカルズ，インク．	プロテアーゼネキシン１変異体を含むキメラ蛋白
ATE214940T1 (de) *	1993-11-10	2002-04-15	Enzon Inc	Verbesserte interferon-polymerkonjugate
US5795776A (en)	1994-03-22	1998-08-18	Bio-Technology General Corp.	Expression plasmids regulated by an OSMB promoter
FI96317C (fi)	1994-05-31	1996-06-10	Exavena Oy	Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de)	1994-07-01	1996-01-04	Bayer Ag	Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en)	1994-09-12	1997-05-27	Miles, Inc.	Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
FI972443A7 (fi)	1994-12-07	1997-06-09	Novozymes As	Polypeptidi, jonka allergeenisuus on vähentynyt
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en)	1995-01-25	1999-08-17	Bio Technology General Corp	Production of enzymatically active recombinant carboxypeptidase b
JP2758154B2 (ja) *	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
FR2733914B1 (fr) *	1995-05-11	1997-08-01	Sanofi Sa	Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja)	1995-12-05	1997-06-17	Asahi Chem Ind Co Ltd	ウリカーゼを生産する実質上純粋な微生物
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
ATE342729T1 (de)	1997-01-15	2006-11-15	Phoenix Pharmacologics Inc	Modifizierter tumor-nekrosefaktor
KR100369838B1 (ko)	1997-02-26	2003-09-29	주식회사 엘지생명과학	한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
JPH1175876A (ja)	1997-07-04	1999-03-23	Ajinomoto Co Inc	新規な微生物トランスグルタミナーゼの製造法
US6821763B2 (en)	1997-07-04	2004-11-23	Ajinomoto Co., Inc.	Process for producing microbial transglutaminase
EP1500661A1 (de) *	1998-06-01	2005-01-26	Genetech, Inc.	Trennung von Protein-Monomeren von Aggregaten mittels Ionaustausch-Chromatographie
US6783965B1 (en) *	2000-02-10	2004-08-31	Mountain View Pharmaceuticals, Inc.	Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20060188971A1 (en)	1998-08-06	2006-08-24	Duke University	Urate oxidase
RU2246318C2 (ru)	1998-08-06	2005-02-20	Маунтэн Вью Фармасьютикэлз, Инк.	Конъюгаты peg-уриказы и их использование
ATE498409T1 (de) *	1998-08-06	2011-03-15	Mountain View Pharmaceuticals	Peg-uricase konjugate und verwendung davon
WO2000008196A2 (en)	1998-08-06	2000-02-17	Duke University	Urate oxidase
US6425448B1 (en) *	2001-01-30	2002-07-30	Cdx Gas, L.L.P.	Method and system for accessing subterranean zones from a limited surface area
US20020068857A1 (en)	2000-02-14	2002-06-06	Iliff Edwin C.	Automated diagnostic system and method including reuse of diagnostic objects
US6913915B2 (en)	2001-08-02	2005-07-05	Phoenix Pharmacologics, Inc.	PEG-modified uricase
KR20030043780A (ko)	2001-11-28	2003-06-02	주식회사 바이오폴리메드	생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법
EP1581644B1 (de)	2003-01-09	2007-06-06	Genentech, Inc.	Reinigung von polypeptiden
JP4273998B2 (ja)	2004-02-26	2009-06-03	学校法人東海大学	プロテオーム解析用試料の調製方法
CN103088038B (zh)	2004-07-12	2015-06-24	美国天甲生物医药有限公司	黄病毒疫苗
US20080159976A1 (en)	2005-04-11	2008-07-03	Jacob Hartman	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
MX2007012548A (es)	2005-04-11	2008-03-11	Savient Pharmaceuticals Inc	Formas variantes de urato oxidasa y uso de las mismas.
US8148123B2 (en) *	2005-04-11	2012-04-03	Savient Pharmaceuticals, Inc.	Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
SG161247A1 (en)	2005-04-11	2010-05-27	Savient Pharmaceuticals Inc	Variant forms of urate oxidase and use thereof
JP5033177B2 (ja)	2006-04-12	2012-09-26	サビエントファーマセウティカルズインク．	陽イオン界面活性剤によるタンパク質の精製
WO2008063663A2 (en)	2006-11-21	2008-05-29	University Of Southern California	Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
US9377454B2 (en)	2009-06-25	2016-06-28	Crealta Pharmaceuticals Llc	Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
JP5746101B2 (ja)	2012-06-18	2015-07-08	コスメディ製薬株式会社	マイクロニードルの迅速溶解法

1999
- 1999-08-02 AT AT05011069T patent/ATE498409T1/de active
- 1999-08-02 PT PT05011069T patent/PT1588716E/pt unknown
- 1999-08-02 CN CN2006100841318A patent/CN1896231B/zh not_active Expired - Fee Related
- 1999-08-02 DE DE69943205T patent/DE69943205D1/de not_active Expired - Lifetime
- 1999-08-02 DK DK99937745T patent/DK1100542T3/da active
- 1999-08-02 CA CA2728907A patent/CA2728907C/en not_active Expired - Fee Related
- 1999-08-02 DK DK10180672.7T patent/DK2316475T3/da active
- 1999-08-02 PT PT99937745T patent/PT1100542E/pt unknown
- 1999-08-02 PT PT101806727T patent/PT2316475T/pt unknown
- 1999-08-02 DE DE69925917T patent/DE69925917T2/de not_active Expired - Lifetime
- 1999-08-02 ES ES09175303T patent/ES2404074T3/es not_active Expired - Lifetime
- 1999-08-02 EP EP05011069A patent/EP1588716B1/de not_active Expired - Lifetime
- 1999-08-02 ES ES99937745T patent/ES2245114T3/es not_active Expired - Lifetime
- 1999-08-02 AT AT99937745T patent/ATE298251T1/de active
- 1999-08-02 CA CA2338665A patent/CA2338665C/en not_active Expired - Fee Related
- 1999-08-02 ES ES05011069T patent/ES2361190T3/es not_active Expired - Lifetime
- 1999-08-02 ES ES10180672.7T patent/ES2649840T3/es not_active Expired - Lifetime
- 1999-08-02 DK DK09175303.8T patent/DK2158923T3/da active
- 1999-08-02 CN CNB998118451A patent/CN1264575C/zh not_active Expired - Fee Related
- 1999-08-02 PT PT91753038T patent/PT2158923E/pt unknown
- 1999-08-02 EP EP10180672.7A patent/EP2316475B1/de not_active Expired - Lifetime
- 1999-08-02 EP EP09175303A patent/EP2158923B1/de not_active Expired - Lifetime
- 1999-08-02 DK DK05011069.1T patent/DK1588716T3/da active
- 1999-08-02 CN CN201010565549.7A patent/CN102161984B/zh not_active Expired - Fee Related
- 1999-08-06 US US09/370,084 patent/US6576235B1/en not_active Expired - Lifetime
2001
- 2001-03-05 ZA ZA200101814A patent/ZA200101814B/en unknown
- 2001-04-19 US US09/839,946 patent/US7723089B2/en not_active Expired - Fee Related
2004
- 2004-08-30 US US10/928,370 patent/US20050014240A1/en not_active Abandoned
2007
- 2007-08-03 US US11/833,590 patent/US7927589B2/en not_active Expired - Fee Related
2010
- 2010-04-28 US US12/769,570 patent/US8067553B2/en not_active Expired - Fee Related
- 2010-04-28 US US12/769,572 patent/US20100323423A1/en not_active Abandoned
2011
- 2011-04-08 US US13/083,152 patent/US8618267B2/en not_active Expired - Fee Related
- 2011-05-09 CY CY20111100446T patent/CY1112287T1/el unknown
- 2011-11-29 US US13/306,336 patent/US20120149083A1/en not_active Abandoned
2014
- 2014-08-18 US US14/462,368 patent/US20140363414A1/en not_active Abandoned
2015
- 2015-07-22 US US14/806,494 patent/US9885024B2/en not_active Expired - Fee Related
2017
- 2017-08-17 US US15/679,401 patent/US20180223263A1/en not_active Abandoned
2018
- 2018-01-02 CY CY20181100001T patent/CY1119848T1/el unknown

Also Published As

Publication number	Publication date
US20100323422A1 (en)	2010-12-23
ES2404074T3 (es)	2013-05-23
US20140363414A1 (en)	2014-12-11
PT1100542E (pt)	2005-11-30
HK1103303A1 (en)	2007-12-14
CN1896231A (zh)	2007-01-17
US20100323423A1 (en)	2010-12-23
CN1264575C (zh)	2006-07-19
US20080031864A1 (en)	2008-02-07
US7723089B2 (en)	2010-05-25
EP2316475A1 (de)	2011-05-04
ES2649840T3 (es)	2018-01-15
ZA200101814B (en)	2002-05-27
CY1119848T1 (el)	2018-06-27
US20160160188A1 (en)	2016-06-09
US8067553B2 (en)	2011-11-29
ES2245114T3 (es)	2005-12-16
PT1588716E (pt)	2011-05-25
DE69943205D1 (de)	2011-03-31
US8618267B2 (en)	2013-12-31
DE69925917T2 (de)	2006-05-11
EP1588716A1 (de)	2005-10-26
ATE298251T1 (de)	2005-07-15
CY1112287T1 (el)	2015-12-09
PT2158923E (pt)	2013-06-04
CN102161984B (zh)	2016-06-01
CA2338665A1 (en)	2000-02-17
CA2338665C (en)	2011-01-18
DK2158923T3 (da)	2013-03-25
US20050014240A1 (en)	2005-01-20
DK1100542T3 (da)	2005-10-17
CA2728907A1 (en)	2000-02-17
DK1588716T3 (da)	2011-05-23
CN102161984A (zh)	2011-08-24
CN1322141A (zh)	2001-11-14
DE69925917D1 (de)	2005-07-28
EP2316475B1 (de)	2017-10-04
HK1037330A1 (en)	2002-02-08
CA2728907C (en)	2015-11-24
CN1896231B (zh)	2012-09-05
US20180223263A1 (en)	2018-08-09
EP1588716B1 (de)	2011-02-16
HK1141738A1 (en)	2010-11-19
ES2361190T3 (es)	2011-06-14
PT2316475T (pt)	2017-12-21
EP2158923B1 (de)	2013-02-27
EP2158923A1 (de)	2010-03-03
DK2316475T3 (da)	2017-11-20
US9885024B2 (en)	2018-02-06
US20030166249A1 (en)	2003-09-04
US7927589B2 (en)	2011-04-19
US6576235B1 (en)	2003-06-10
US20130052677A1 (en)	2013-02-28
US20120149083A1 (en)	2012-06-14

Legal Events

Date

Code

Title

Description

2011-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1588716

Country of ref document: EP

Publication	Publication Date	Title
ATE498409T1 (de)	2011-03-15	Peg-uricase konjugate und verwendung davon
NZ509595A (en)	2004-02-27	Peg-urate oxidase conjugates and use thereof
AU7761594A (en)	1995-01-12	Polyethylene glycols
HK1054684A1 (zh)	2003-12-12	包含高分子量聚环氧乙烷的多价平台分子
ATE516820T1 (de)	2011-08-15	Pegyliertes interleukin 10
IL193365A0 (en)	2009-02-11	Aggregate-free urate oxidases, polymer conjugates thereof and compositions prepared therefrom
WO2003055526A3 (en)	2003-12-11	Erythropoietin conjugates
RU2002120486A (ru)	2004-08-20	Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
CA2304976A1 (en)	1999-05-14	Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
IL197339A (en)	2015-02-26	Recombinant chimeric uricase protein, protein-containing linker and preparations containing them
WO2001002017A3 (en)	2001-08-09	Erythropoietin conjugates with polyethylenglycol
CA2323048A1 (en)	1999-09-16	Poly(ethylene glycol) derivatives with proximal reactive groups
PT1517710E (pt)	2011-07-08	Glicoformas do factor vii peguilado
ATE385422T1 (de)	2008-02-15	Bisacyloxypropylcystein-konjugate und deren verwendung
WO2005084303A3 (en)	2006-08-17	Interferon-beta polymer conjugates
CY1114005T1 (el)	2016-07-27	Συζευγματα peg-ουρικης οξειδασης και χρηση αυτων
EP1025860A3 (de)	2002-06-19	Proteinhaltige Hydrogele